inhibitor treatment, comprising administering an effective amount of a compound disclosed herein.

[006a] In one aspect of the present disclosure, there is provided a compound represented by:



.

[006b] In another aspect of the present disclosure, there is provided a compound, wherein the compound is 5-{(7*R*)-1-fluoro-3-hydroxy-7-[(3-methylbutyl)amino]-5,6,7,8-tetrahydronaphthalen-2-yl}-1λ^6,2,5-thiadiazolidine-1,1,3-trione, or a pharmaceutically acceptable salt thereof.

[006c] In a further aspect of the present disclosure, there is provided a pharmaceutically acceptable composition comprising a compound disclosed herein and a pharmaceutically acceptable carrier.

[007] For example, disclosed herein is a compound represented by Formula (I):



(I);

CLAIMS

1. A compound represented by:



.

2. A compound, wherein the compound is 5-{(7*R*)-1-fluoro-3-hydroxy-7-[(3-methylbutyl)amino]-5,6,7,8-tetrahydronaphthalen-2-yl}-1λ^6,2,5-thiadiazolidine-1,1,3-trione, or a pharmaceutically acceptable salt thereof.

3. The compound of claim 2, wherein the compound is the pharmaceutically acceptable salt of 5-{(7*R*)-1-fluoro-3-hydroxy-7-[(3-methylbutyl)amino]-5,6,7,8-tetrahydronaphthalen-2-yl}-1λ^6,2,5-thiadiazolidine-1,1,3-trione.

4. A pharmaceutically acceptable composition comprising a compound of any one of claims 1-3 and a pharmaceutically acceptable carrier.

5. The composition of claim 4, wherein the composition is formulated for oral administration.